Perrigo’s Loss Is Lupin’s Gain On Albuterol
As Lupin’s Somerset Site Gets 13 Observations Following FDA Inspection
Having gained from Perrigo’s US withdrawal of generic ProAir (albuterol sulphate), Lupin plans to ramp up capacity by its financial fourth quarter as demand is seen rising on account of flu and COVID-19 cases in the US. Meanwhile, FDA observations at its Somerset facility provide a dampener.
